ArriVent BioPharma

AVBP · Nasdaq · United States

Share price · AVBP

$10.90-19.10 (-63.67%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.7M (1.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AVBP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 26 Oct 2026-26.9%
  2. 6 Oct 2026-47.0%
  3. 25 Aug 2026+10.9%
  4. 22 Jul 2026+7.7%
  5. 20 Jul 2026-15.0%
  6. 24 Jun 2026-5.1%
  7. 4 Jun 2026+11.1%
  8. 29 May 2026+12.2%
  9. 20 Apr 2026+5.9%
  10. 9 Apr 2026+7.9%

    Nothing announced by AVBP that day or the session before.

Share of unusual movement by asset

For each asset, the share of AVBP's own-move activity since 3 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Furmonertinib
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—38%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—46%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
FurmonertinibPhase 3Non-small Cell Lung Carcinoma
Est. primary completion 2026-12 · NCT04853342 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
FurmonertinibPhase 3EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Est. primary completion 2027-12 · NCT06956001 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
FurmonertinibPhase 3NSCLC, Adjuvant Treatment
Est. primary completion 2028-10-31 · NCT07010419 · CT.gov ↗
What to watch
2029 (2)
February 2029 (1)
FurmonertinibPhase 3Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer …
Est. primary completion 2029-02 · NCT07185997 · CT.gov ↗
What to watch
March 2029 (1)
FurmonertinibPhase 3NSCLC Patients With Brain Metastasis
Est. primary completion 2029-03 · NCT06970639 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 October 2026Topline resultFurmonertinibArriVent reports the Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 NSCLC missed its primary PFS endpoint
ArriVent BioPharma · Source ↗

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$5.0M$39M$114M+ $280M short-term inv.$40M-$41M operating cash flowreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$42M$155M+ $218M short-term inv.$50M-$40M operating cash flowreport ↗
2026-Q1—$38M$62M+ $264M short-term inv.$43M-$42M operating cash flowreport ↗
2025-Q3—$32M$113M+ $188M short-term inv.$35M-$36M operating cash flowreport ↗
2025-Q2—$28M$113M+ $123M short-term inv.$31M-$26M operating cash flowreport ↗
2025-Q1—$61M$50M+ $126M short-term inv.$64M-$68M operating cash flowreport ↗
2024-Q3—$20M$283M$21M-$16M operating cash flowreport ↗
2024-Q2—$22M$299M$22M-$19M operating cash flowreport ↗
2024-Q1—$17M$317M$17M-$19M operating cash flowreport ↗
2023-Q3—$14M$141M$14M-$15M operating cash flowreport ↗
2023-Q2—$20M$158M$22M-$8.6M operating cash flowreport ↗
2023-Q1—$10M$191M$12M-$17M operating cash flowreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$153M$46M+ $267M short-term inv.$42M-$161M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$79M$74M+ $145M short-term inv.$20M-$70M operating cash flowreport ↗
2023-FY—$65M$150M$17M-$56M operating cash flowreport ↗
2022-FY——$163M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($13.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-30LaChapelle Robin · Chief Operating OfficerOption exercise16,265$3.65$59KForm 4
2026-10-30LaChapelle Robin · Chief Operating OfficerOption exercise410$2.28$935Form 4
2026-10-30LaChapelle Robin · Chief Operating OfficerOption exercise4,550$2.28$10KForm 4
2026-10-30LaChapelle Robin · Chief Operating OfficerOption exercise1,820$2.28$4KForm 4
2026-10-30LaChapelle Robin · Chief Operating OfficerOption exercise17,648$6.24$110KForm 4
2026-10-30LaChapelle Robin · Chief Operating OfficerOption exercise (derivative)410——Form 4
2026-10-30LaChapelle Robin · Chief Operating OfficerOption exercise (derivative)4,550——Form 4
2026-10-30LaChapelle Robin · Chief Operating OfficerOption exercise (derivative)1,820——Form 4